CytomX Therapeutics Appoints Yu-Waye (Wayne) Chu, M.D., as Chief Medical Officer
2023年7月17日 - 9:00PM
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of
conditionally activated, localized biologics, today announced the
appointment of Yu-Waye (Wayne) Chu, M.D., as Chief Medical Officer
(CMO). In this role, Dr. Chu will oversee clinical development of
the Company’s diversified portfolio of Probody® therapeutic
candidates.
“Wayne brings to CytomX substantial experience
in clinical development strategy in the oncology space,” said Sean
McCarthy, D.Phil., chief executive officer and chairman of CytomX
Therapeutics. “His drug development experiences have contributed to
multiple approvals and span therapeutic modalities including
antibody drug conjugates, checkpoint inhibitors, and bispecific
immunotherapies, making him an ideal fit to lead the development of
CytomX’s robust and differentiated pipeline. Wayne joins CytomX at
a moment where we are expecting to make significant clinical
progress with our next generation pipeline including the continued
advancement of CX-904 through Phase 1, the initial clinical
strategies for our new INDs, CX-2051 and CX-801, and our ongoing
efforts aimed at targeting CD71.”
“I am very pleased to be joining CytomX at a
time when the pipeline is positioned to make important clinical
progress across multiple programs. The Probody® Platform and
CytomX’s leadership in localized biologics has resulted in a
compelling pipeline of drug candidates and a meaningful opportunity
to create near- and long-term value for patients,” said Dr. Chu. “I
look forward to working with the team on our shared goal of
bringing new and differentiated treatments to people with cancer
and advancing our leadership in the field of biologics
localization.”
Dr. Chu joins CytomX with over 20 years of
experience in oncology, in roles ranging from research to medicine
to global clinical development. He was previously Chief Medical
Officer at Fate Therapeutics, where he oversaw the company’s
clinical development strategies of novel immune cell therapies for
the treatment of hematologic and solid tumor malignancies. Prior to
joining Fate, Wayne spent a decade at Genentech, where he assumed
positions of increasing responsibility in Product Development
Oncology in the development of the HER2-directed antibody drug
conjugate trastuzumab emtansine (Kadcyla). He then joined the Early
Clinical Development group in Genentech Research and Early
Development in 2011 where he led the early clinical development of
molecules covering multiple therapeutic platforms including
antibody drug conjugates, checkpoint inhibitors, and immune cell
bispecific antibodies, notably the development of polatuzumab
vedotin (anti-CD79b antibody drug conjugate), tiragolumab
(anti-TIGIT monoclonal antibody) and mosunetuzumab (CD20/CD3
bispecific antibody), and continued to lead the global development
of mosunetuzumab in his role in Product Development Oncology at
Roche/Genentech. Prior to his clinical development experience, Dr.
Chu conducted his clinical training in pediatric
hematology-oncology at Johns Hopkins School of Medicine and the
National Cancer Institute. He graduated cum laude with a B.A. in
Molecular Biology from Princeton University and earned his M.D.
with Distinction in Research from the University of Rochester
School of Medicine and Dentistry.
About CytomX
TherapeuticsCytomX is a clinical-stage, oncology-focused
biopharmaceutical company focused on developing novel conditionally
activated biologics localized to the tumor microenvironment. By
pioneering a novel class of conditionally activated biologics,
powered by its Probody® technology platform, CytomX’s goal is to
transcend the limits of current cancer treatments. CytomX’s robust
and differentiated pipeline comprises therapeutic candidates across
multiple treatment modalities including antibody-drug conjugates
(“ADCs”), T-cell engaging bispecific antibodies (“TCBs”), and
immune modulators such as cytokines and checkpoint inhibitors
(“CPIs”). CX-2029 is an investigational conditionally activated
antibody-drug conjugate (ADC) directed toward CD71. CytomX’s
clinical pipeline also includes cancer immunotherapeutic candidates
against validated targets such as the CTLA-4-targeting Probody
therapeutic BMS-986288, partnered with Bristol Myers Squibb,
as well as CX-904, a conditionally activated T-cell-engaging
bispecific antibody targeting the epidermal growth factor receptor
(EGFR) on tumor cells and the CD3 receptor on T cells, which is
partnered with Amgen. In addition, CytomX has a diverse preclinical
portfolio of wholly-owned assets including CX-801, an interferon
alpha-2b Probody cytokine that has broad potential applicability in
traditionally immuno-oncology sensitive as well as insensitive
(cold) tumors and CX-2051, a conditionally activated ADC directed
toward EpCAM, with potential applicability across multiple
EpCAM-expressing epithelial cancers. CytomX has also established
strategic collaborations with multiple leaders in oncology,
including Amgen, Astellas, Bristol Myers Squibb, Regeneron and
Moderna. For more information about CytomX and how it is working to
make conditionally activated treatments the new standard-of-care in
the fight against cancer,
visit www.cytomx.com and follow us
on LinkedIn and Twitter.
CytomX Therapeutics Forward-Looking
Statements
This press release includes forward-looking
statements. Such forward-looking statements involve known and
unknown risks, uncertainties and other important factors that are
difficult to predict, may be beyond our control, and may cause the
actual results, performance, or achievements to be materially
different from any future results, performance or achievements
expressed or implied in such statements, including those related to
the future potential of partnerships or collaboration agreements.
Accordingly, you should not rely on any of these forward-looking
statements, including those relating to the potential benefits,
safety and efficacy or progress of CytomX’s or any of its
collaborative partners’ product candidates, including CX-2029,
BMS-986288, CX-904, CX-801, and CX-2051, the potential benefits or
applications of CytomX’s Probody platform technology, CytomX’s
ability to develop and advance product candidates into and
successfully complete clinical trials, including the ongoing and
planned clinical trials of BMS-986288, and CX-904, and the timing
of the commencement of clinical trials, initial and ongoing data
availability, and the timing of investigational new drug
applications, including for CX-801 and CX-2051, and other
development milestones. Risks and uncertainties that contribute to
the uncertain nature of the forward-looking statements include: the
unproven nature of CytomX’s novel Probody Platform technology;
CytomX’s clinical trial product candidates are in the initial
stages of clinical development and its other product candidates are
currently in preclinical development, and the process by which
preclinical and clinical development could potentially lead to an
approved product is long and subject to significant risks and
uncertainties, including the risk that the COVID-19 worldwide
pandemic may continue to negatively impact the business, research
and clinical operations of CytomX or its partners, including the
development of preclinical drug candidates due to delays in and
disruption of research activities and the development of clinical
drug candidates due to delays in or disruption of clinical trials,
including impacts on the enrollment of patients in clinical trials
or other clinical trial disruptions; the possibility that the
results of preclinical research and early clinical trials may not
be predictive of future results; the possibility that CytomX’s
clinical trials will not be successful; the possibility that
current preclinical research may not result in additional product
candidates; CytomX’s dependence on the success of CX-2029,
BMS-986288, CX-904, CX-801, and CX-2051; CytomX’s reliance on third
parties for the manufacture of the Company’s product candidates;
and possible regulatory developments in the United States and
foreign countries. Additional applicable risks and uncertainties
include those relating to our preclinical research and development,
clinical development, and other risks identified under the heading
"Risk Factors" included in CytomX’s Quarterly Report on Form 10-Q
filed with the SEC on May 9, 2023. The forward-looking statements
contained in this press release are based on information currently
available to CytomX and speak only as of the date on which they are
made. CytomX does not undertake and specifically disclaims any
obligation to update any forward-looking statements, whether as a
result of any new information, future events, changed circumstances
or otherwise.
Probody is a U.S. registered trademark of CytomX
Therapeutics, Inc.
CytomX Contact:Chris OgdenSVP,
Finance and Accounting cogden@cytomx.com(317) 767-4764
Investor and Media
Contact:Stern Investor RelationsStephanie
Ascherstephanie.ascher@sternir.com212-362-1200
CytomX Therapeutics (NASDAQ:CTMX)
過去 株価チャート
から 6 2024 まで 7 2024
CytomX Therapeutics (NASDAQ:CTMX)
過去 株価チャート
から 7 2023 まで 7 2024